甲基胺诱导的血压敏感化与A1/C1甲基胺神经元内的形态变化相关
Carla Letizia Busceti1, Domenico Bucci1, Antonio Damato1
1Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Neuromed, 86077 Pozzilli, Italy.
International journal of molecular sciences
|October 16, 2024
概括
重复使用甲基胺 (METH) 会使血压敏感,并减少大脑干中的关键神经元.
科学领域:
- 神经科学是一个神经科学.
- 心血管科学 心血管科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 甲基胺 (METH) 是一种强烈的精神刺激药物,具有显著的滥用潜力.
- 众所周知,重复使用METH可以诱导行为敏感化.
- 甲会影响心血管功能,包括血压,但根本的神经机制尚未完全理解.
研究的目的:
- 调查重复的METH给药是否会使抽缩和腹缩血压 (SBP和DBP) 变得敏感.
- 为了确定METH暴露后大脑干血管运动中心A1/C1神经元内是否发生变化.
- 探索与METH诱导的心血管效应相关的细胞和分子变化.
主要方法:
- C57Bl/6J雄性小鼠每天接受METH (5 mg/kg) 连续5天.
- 血压 (SBP和DBP) 通过尾巴手胸膜学来监测.
- 免疫组织化学被用来评估甲基胺神经元,谷氨酸脱碳酶,以及神经元应激和退化标志物 (Fluoro-Jade B,α-synuclein,-cJun,热冲击蛋白-70,p62/sequestosome).
主要成果:
- 在多次使用METH后,在SBP和DBP中都观察到敏感反应.
- 在腹侧髓的A1/C1区域内发现了甲基胺神经元的显著减少.
- 这种神经元的减少与自由基和-cJun的减少,以及热冲击蛋白-70和p62/sequestosome的增加有关,但不是退化标志物.
- 动脉反应性保持不变,这表明血压敏感化的中心机制.
结论:
- 重复给予METH可能会导致血压持续升高.
- METH可能会使心血管反应敏感,可能会增加不良事件的风险.
- 这些发现突显了METH诱导的心血管并发症的神经生物学基础及其在压力环境中的相关性.
相关概念视频
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
166
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
166
Adrenergic Agonists: Indirect-Acting Agents
1.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.5K
Adrenergic Neurons: Neurotransmission
3.4K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
Synthesis: Catecholamine synthesis requires tyrosine, which...
3.4K
Drugs Affecting Neurotransmitter Release or Uptake
970
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
970
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Drugs Acting on Autonomic Ganglia: Stimulants
1.3K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.3K


